Proactive Investors - Run By Investors For Investors

Sativa Investments' investee firm Rapid Dose Therapeutics begins trading on CSE

Rapid Dose Therapeutics has made an initial paper profit of C$140,000 for Savita Investments, an increase of 70%, after just seven months
cannanis
Rapid Dose Therapeutics has developed a fast-dissolving medicinal cannabis strip

Bio-technology firm Rapid Dose Therapeutics Inc (CSE:DOSE), an investee business of medicinal cannabis investor Sativa Investments PLC (LON:SATI), has been admitted to trading on the Canadian Stock Exchange.

Sativa Investments, which is the UK’s first medicinal cannabis investment firm, subscribed for 400,000 shares at C$50 each in Rapid Dose Therapeutics for C$200,000 in cash ahead of the listing on Monday.

At the close on Monday, shares were trading hands at C$0.85 each.

WATCH: Sativa Investments 'at the forefront' of developing UK medical cannabis market

Rapid Dose Therapeutics has developed a fast-dissolving medicinal cannabis strip, called Quickstrip, that is placed on or under the tongue, or inside the cheek. The company also sells pharmaceuticals, emulsified oils and over-the-counter medicines across North America.

The firm has made an initial paper profit of C$140,000 for Savita Investments, an increase of 70%, after just seven months.

"RDT's technology has very positive implications for both Sativa's medicinal cannabis business and its CBD (cannabidiol) focused 100% subsidiary George Botanicals Limited, and we look forward to continued collaboration with RDT alongside our investment." 

View full SATI profile View Profile

Sativa Investments Timeline

Related Articles

microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
Sativa
April 02 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has made significant progress since it started trading on NEX.
researcher
April 30 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use